Convergent Therapeutics, Inc.
Danielle Quarles, MPH, serves as the Vice President of Clinical Operations at Convergent Therapeutics, Inc. since March 2025. Prior to this role, Danielle held positions at Sana Biotechnology, Inc., including Executive Director and Senior Director of Clinical Operations from August 2021 to January 2025. Danielle's extensive experience also includes leadership roles at ICON plc, where responsibilities encompassed Senior Director of Project Management in Infectious Diseases & Vaccines and Director of Project Management in Oncology & Cell Therapeutics. Additional positions were held at PAREXEL, PRA International, MedImmune, and The EMMES Corporation, showcasing a strong background in clinical project management and operation across various organizations. Danielle holds a Master of Public Health in Epidemiology from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science in Animal and Poultry Sciences from Virginia Tech.
This person is not in any teams
This person is not in any offices
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.